Sponsor
University of California, San Francisco
Status
Recruiting
ClinicalTrials.gov ID
For more information, see ClinicalTrials.gov NCT03933670
This phase II trial studies the side how well hyperpolarized carbon C 13 pyruvate (HP C-13 pyruvate) magnetic resonance imaging (MRI) works in monitoring patients with prostate cancer on active surveillance who have not received treatment. Diagnostic procedures, such as MRI, may help visualize HP C-13 pyruvate uptake and breakdown in tumor cells.
Intervention
Hyperpolarized Carbon C 13 Pyruvate, MRI Ultrasound Fusion Guided Biopsy, Magnetic Resonance Spectroscopic Imaging
Condition
Prostate Adenocarcinoma, Prostate Cancer
Investigators
Ivan de Kouchkovsky, MD, None, Louise Magat